TY - JOUR
T1 - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
AU - Galsky, Matthew D.
AU - Balar, Arjun V.
AU - Black, Peter C.
AU - Campbell, Matthew T.
AU - Dykstra, Gail S.
AU - Grivas, Petros
AU - Gupta, Shilpa
AU - Hoimes, Christoper J.
AU - Lopez, Lidia P.
AU - Meeks, Joshua J.
AU - Plimack, Elizabeth R.
AU - Rosenberg, Jonathan E.
AU - Shore, Neal
AU - Steinberg, Gary D.
AU - Kamat, Ashish M.
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2021/7/15
Y1 - 2021/7/15
N2 - A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.
AB - A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.
KW - antineoplastic protocols
KW - guidelines as topic
KW - immunotherapy
KW - urinary bladder neoplasms
KW - urologic neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85110462459&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110462459&partnerID=8YFLogxK
U2 - 10.1136/jitc-2021-002552
DO - 10.1136/jitc-2021-002552
M3 - Article
C2 - 34266883
AN - SCOPUS:85110462459
SN - 2051-1426
VL - 9
JO - Journal for immunotherapy of cancer
JF - Journal for immunotherapy of cancer
IS - 7
M1 - e002552
ER -
